公开(公告)号：US06328979B1

公开(公告)日：2001-12-11

申请号：US09582384

申请日：2000-06-23

申请人： Noboru Yamashita ,  Akira Takagi ,  Masataka Katsuma ,  Katsumi Saito ,  Yuuki Takaishi ,  Tatsuo Yasuda ,  Yutaka Takahashi ,  Mitsuo Mitomi

发明人： Noboru Yamashita ,  Akira Takagi ,  Masataka Katsuma ,  Katsumi Saito ,  Yuuki Takaishi ,  Tatsuo Yasuda ,  Yutaka Takahashi ,  Mitsuo Mitomi

IPC分类号： A61K900

CPC分类号： A61K9/0024 ,  A61K9/0019 ,  A61K9/06 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/186 ,  A61K47/20 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44

摘要： The present invention relates to sustained-release pharmaceutical compositions for ionic pharmaceutically active substances (excluding ionic prostanoic acid derivatives) containing ionic compounds having opposite charges to those of the active substances and increasing hydrophobicity of the active substances. More specifically, the invention relates to sustained-release pharmaceutical compositions comprising the ionic pharmaceutically active substances and the ionic compounds having opposite charges to those of the active substances and increasing hydrophobicity of the active substances that contain hydrophobic groups in the molecule thereof. The pharmaceutical composition of the invention can exhibit excellent sustained release effect of the active substance, irrespective of water solubility possessed by the ionic pharmaceutically active substances.

摘要翻译： 本发明涉及含有与活性物质具有相反电荷的离子化合物的离子药物活性物质（不含离子前列腺酸衍生物）的持续释放药物组合物，并且活性物质的疏水性增加。 更具体地，本发明涉及包含离子药物活性物质和具有与活性物质相反的电荷的离子化合物的缓释药物组合物，并且其分子中含有疏水基团的活性物质的疏水性增加。 本发明的药物组合物可以表现出优异的活性物质的缓释作用，而与离子药物活性物质所具有的水溶性无关。

公开(公告)号：US06919372B1

公开(公告)日：2005-07-19

申请号：US09582404

申请日：1998-12-25

申请人： Noboru Yamashita ,  Akira Takagi ,  Masataka Katsuma ,  Katsumi Saito ,  Yuuki Takaishi ,  Tatsuo Yasuda ,  Yutaka Takahashi ,  Mitsuo Mitomi ,  Michio Hara

发明人： Noboru Yamashita ,  Akira Takagi ,  Masataka Katsuma ,  Katsumi Saito ,  Yuuki Takaishi ,  Tatsuo Yasuda ,  Yutaka Takahashi ,  Mitsuo Mitomi ,  Michio Hara

IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61K47/20 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A01N43/08 ,  A61K31/34

CPC分类号： A61K9/0024 ,  A61K9/0019 ,  A61K9/06 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/186 ,  A61K47/20 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44

摘要： The present invention relates to sustained-release pharmaceutical compositions for ionic pharmaceutically active substances containing ionic compounds having opposite charges to those of ionic prostanoic acid derivatives and increasing hydrophobicity of the active substances. More specifically, the invention relates to sustained-release pharmaceutical compositions comprising the ionic prostanoic acid derivatives and the ionic compounds having opposite charges to those of the prostanoic acid derivatives and increasing hydrophobicity of these derivatives that contain hydrophobic groups in the molecule thereof.The pharmaceutical composition of the invention can exhibit excellent sustained release effect of the ionic prostanoic acid derivatives, irrespective of water solubility possessed by the ionic prostanoic acid derivatives.

摘要翻译： 本发明涉及含离子化合物的离子药物活性物质的缓释药物组合物，其具有与离子前列腺酸衍生物相反的电荷并增加活性物质的疏水性。 更具体地，本发明涉及包含离子前列腺酸衍生物和具有与前列腺酸衍生物相反电荷的离子化合物的缓释药物组合物，并且在其分子中含有疏水基团的这些衍生物的疏水性增加。 本发明的药物组合物可以表现出优异的离子前列腺酸衍生物的缓释作用，而与离子前列腺酸衍生物具有的水溶性无关。